Phase 1Completed
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
- Sponsor
- Orphelia Pharma (Industry)
- Enrollment
- 36 enrolled
- Conditions
- Therapeutic Equivalency
- Interventions
- Ped-TMZ
- Ages
- adults, older adults
- Registry
- NCT04467346
Full record on ClinicalTrials.gov
From the registry
Primary objective: • Evaluate bioequivalence between Temozolomide Oral Suspension and Temodal® capsules for oral administration. Secondary objectives: * Define the pharmacokinetic parameters of Temozolomide Oral Suspension. * Assess the buccal safety of Temozolomide Oral Suspension.
Primary outcomes
- Primary pharmacokinetic parameter: Cmax
- Primary pharmacokinetic parameter: AUC0-t
History
Last registry update
Primary completion
Started
Registered